Everolimus Treatment for Neuroendocrine Tumors: Latest Results and Clinical Potential

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2017 Mar 28

PMID 28344663

Citations 16

Authors

Sara Pusceddu

Elena Verzoni

Natialie Prinzi

Alessia Mennitto

Daniela Femia

Paolo Grassi

Laura Concas

Claudio Vernieri

Giuseppe Lo Russo

Giuseppe Procopio

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous class of diseases characterized by challenging management. Preclinical evidence shows that the PI3K/AKT/mTOR signaling pathway plays a central role in the pathogenesis and progression of NETs. Everolimus is a direct inhibitor of this pathway, and therefore this molecule appears to be a well-grounded strategy for the treatment of NETs, capable of changing clinical practice. The efficacy and safety of everolimus was demonstrated in the RADIANT trials. In this work, we comment on the results of the RADIANT trials, and other recent key evidence from fully published clinical trials on everolimus, and we discuss the current role of everolimus in the treatment of NETs.

Citing Articles

Hypoxia drives CBR4 down-regulation promotes gastroenteropancreatic neuroendocrine tumors via activation mammalian target of rapamycin mediated by fatty acid synthase.

Ye M, Xu L, Lu F, Chen L, Hu C, Chen J J Cell Commun Signal. 2024; 18(3):e12041.

PMID: 39524139 PMC: 11544642. DOI: 10.1002/ccs3.12041.

The Role of Inositols in Endocrine and Neuroendocrine Tumors.

Mormando M, Puliani G, Bianchini M, Lauretta R, Appetecchia M Biomolecules. 2024; 14(8).

PMID: 39199391 PMC: 11353224. DOI: 10.3390/biom14081004.

Incidentally Found Rectal Carcinoid Tumor in a 46-Year-Old Female: The Potential for Complications and the Importance of Screening Guidelines.

Lapides R, Shah A, Bal S Cureus. 2024; 16(2):e55163.

PMID: 38558605 PMC: 10980541. DOI: 10.7759/cureus.55163.

Comparative Survival Benefits of Surgery and Adjuvant Chemotherapy in Neuroendocrine Carcinoma of the Gallbladder: A Population-Based Study with Insight into Future Personalized Therapeutic Approach.

Khan J, Ullah A, Yasinzai A, Waheed A, Ballur K, Dickerson T J Pers Med. 2023; 13(6).

PMID: 37373998 PMC: 10305167. DOI: 10.3390/jpm13061009.

Values of debulking surgery for unresectable well-differentiated metastatic pancreatic neuroendocrine tumors: a comparative study.

Huang X, Xie J, Chen L, Cai J, Chen W, Liang L Gastroenterol Rep (Oxf). 2023; 11:goad010.

PMID: 36911142 PMC: 9995090. DOI: 10.1093/gastro/goad010.

References

Yao J, Phan A, Chang D, Wolff R, Hess K, Gupta S . Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008; 26(26):4311-8. PMC: 2653122. DOI: 10.1200/JCO.2008.16.7858. View

Bajetta E, Catena L, Fazio N, Pusceddu S, Biondani P, Blanco G . Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014; 120(16):2457-63. DOI: 10.1002/cncr.28726. View

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

Pusceddu S, De Braud F, Concas L, Bregant C, Leuzzi L, Formisano B . Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori. 2015; 100(6):e286-9. DOI: 10.1700/1778.19298. View

Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A . Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discov Today. 2013; 19(4):458-68. DOI: 10.1016/j.drudis.2013.10.015. View

Pusceddu S, Tessari A, Testa I, Procopio G . Everolimus in advanced solid tumors: when to start, early or late?. Tumori. 2014; 100(1):e2-3. DOI: 10.1700/1430.15827. View

Pusceddu S, De Braud F, Lo Russo G, Concas L, Femia D, Vernieri C . How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget. 2016; 7(28):44841-44847. PMC: 5190138. DOI: 10.18632/oncotarget.8601. View

Ferolla P . Medical treatment of advanced thoracic neuroendocrine tumors. Thorac Surg Clin. 2014; 24(3):351-5. DOI: 10.1016/j.thorsurg.2014.05.006. View

Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L . Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. Future Oncol. 2016; 12(10):1251-60. DOI: 10.2217/fon-2015-0077. View

10.

Castellano D, Bajetta E, Panneerselvam A, Saletan S, Kocha W, ODorisio T . Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study. Oncologist. 2012; 18(1):46-53. PMC: 3556255. DOI: 10.1634/theoncologist.2012-0263. View

11.

Kulke M, Lenz H, Meropol N, Posey J, Ryan D, Picus J . Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008; 26(20):3403-10. DOI: 10.1200/JCO.2007.15.9020. View

12.

Procopio G, Pusceddu S, Buzzoni R . Sunitinib and everolimus in pancreatic neuroendocrine tumors. Tumori. 2012; 98(3):394. DOI: 10.1177/030089161209800319. View

13.

Yao J, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E . Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2015; 387(10022):968-977. PMC: 6063317. DOI: 10.1016/S0140-6736(15)00817-X. View

14.

Pavel M, Hainsworth J, Baudin E, Peeters M, Horsch D, Winkler R . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808):2005-2012. DOI: 10.1016/S0140-6736(11)61742-X. View

15.

Yao J, Shah M, Ito T, Bohas C, Wolin E, Van Cutsem E . Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):514-23. PMC: 4208619. DOI: 10.1056/NEJMoa1009290. View

16.

Fazio N, Granberg D, Grossman A, Saletan S, Klimovsky J, Panneerselvam A . Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. Chest. 2012; 143(4):955-962. DOI: 10.1378/chest.12-1108. View

17.

Panzuto F, Rinzivillo M, Fazio N, De Braud F, Luppi G, Zatelli M . Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist. 2014; 19(9):966-74. PMC: 4153458. DOI: 10.1634/theoncologist.2014-0037. View

18.

Lombard-Bohas C, Yao J, Hobday T, Van Cutsem E, Wolin E, Panneerselvam A . Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial. Pancreas. 2014; 44(2):181-9. PMC: 4327560. DOI: 10.1097/MPA.0000000000000262. View

19.

Ito T, Okusaka T, Nishida T, Yamao K, Igarashi H, Morizane C . Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs. 2012; 31(5):1265-74. PMC: 3771378. DOI: 10.1007/s10637-012-9910-y. View

20.

Manfredi G, Dicitore A, Gaudenzi G, Caraglia M, Persani L, Vitale G . PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. Endocrine. 2014; 48(2):363-70. DOI: 10.1007/s12020-014-0380-1. View